Clinical trial
Evaluation of Consistency of StaphVAX Manufacturing Lots
NCT00211991 · Nabi Biopharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00211991 |
|---|---|
| Title | Evaluation of Consistency of StaphVAX Manufacturing Lots |
| Official title | A Phase 3, Multicenter, Double-Blinded, Randomized, Study to Compare Immunogenicity and Safety Between Three Commercial Lots of StaphVAX®, a Bivalent Staphylococcus Aureus Glycoconjugate Vaccine in Normal, Healthy, Adult Volunteers |
| Lead sponsor | Nabi Biopharmaceuticals, Industry |
| Collaborators | Vanderbilt University |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Staphylococcal Infections |
| Intervention type | Biological |
| Interventions | S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate |
| Enrollment | 354 |
| Start date | Apr 1, 2005 |
| Primary completion | Jul 1, 2005 |
| Completion | Jul 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | May 14, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: